Website swissbiotech.org

Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441

• ADX71441 produced dose-dependent changes on growth hormone (GH) plasma concentrations in a preclinical model
• The data confirms the role of gamma-aminobutyric acid (GABA) in modulating GH plasma concentrations previously reported in humans and animals
• GH plasma concentrations occurred at doses and plasma concentrations of ADX71441 which have been demonstrated to induce pharmacological and efficacious effects in preclinical models of CMT1A, anxiety, pain, overactive bladder and alcohol addiction
• ADX71441 on track to initiate Phase 1 testing in H1 2013

Merck: Lust auf Risiko

Doppelt gut: Maria Rohm vom DKFZ

Hamburger Preis für Tübinger Hirnforscher